Portfolio
Across two funds, we back early-stage medtech companies whose technologies have the potential to reshape diagnosis, treatment, and the standard of care.

Caption Health
7× Return
Geneva Health Solutions
3× Return

Fund II was a $2.5M fund backed by 56 Accredited Investor Limited Partners, writing checks of $50K–$250K into early-stage medtech companies. Both Highcroft funds are closed to new investment.
The fund employs industry-standard investor management, tracking, compliance, and tax software to ensure streamlined, transparent, and regulatory-compliant operations.
Our Approach
Learn how a team of physician investors evaluates and supports the medtech companies redefining care.
Our philosophy →